Oppenheimer boosted its price target on Outperform-rated Keryx Biopharmaceuticals (NASDAQ: KERX) from $3 to $11 following positive Phase III trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE